Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Marie Skłodowska-Curie Action · Ended early

KetoFAPIs Next generation ketoamide inhibitors of fibroblast activation protein (FAP) to revolutionize radionuclide therapy in cancer.

Coordinator
Universiteit Antwerpen, Belgium
Runs
1 November 2024 to 31 October 2026
Status
Ended early
EU funding
€192k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101155227

What the project is doing

In the project's own words, from its summary on CORDIS.

Fibroblast activation protein (FAP) is a serine protease that is highly expressed on cancer-associated-fibroblasts (CAFs), in nearly all tumor types. Its limited presence in healthy tissues makes it an attractive diagnostic and therapeutic biomarker for cancer. UAMC1110, a potent and specific FAP inhibitor discovered by the host, opened the way for the development of the so-called ‘FAPIs’. These are tumor-targeting molecules composed of a UAMC1110 moiety and a radionuclide.

The latter can either be a diagnostic radionuclide for PET imaging, or a more cytotoxic radionuclide for cancer therapy. Radiodiagnostic FAPIs are now entering clinical practice, but their therapeutic counterparts face challenges, related to the relatively short tumor residence time of currently available molecules. The latter leads to significant ‘leaking’ of toxic radioactivity from the tumor. To overcome this issue, we will develop ‘ketoFAPIs’ that form long-lived covalent bonds with FAP.

This should already ensure significantly longer tumor residence. The ketoFAPIs will also be bound to the surface of gold nanoparticles (AuNPs). The resulting constructs could have further increased tumor residence through the ‘multivalency’ effect. This interdisciplinary proposal covers 1) the chemical preparation of novel ketoFAPIs and derived AuNPs, 2) their in vitro characterization and 3) in vivo investigation in a mouse model of colorectal cancer.

Overall, the project can lead to safer and more efficient FAPIs for radiotherapy applications. The status of FAP as a ‘pan-cancer’ biomarker entails that these FAPIs could be applied in nearly all cancer types.

Topics

Who is involved

OrganisationCityCountryRole
Universiteit AntwerpenAntwerpenBelgiumCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI